CN104755474A - Tec家族激酶抑制剂疗法的伴随诊断 - Google Patents

Tec家族激酶抑制剂疗法的伴随诊断 Download PDF

Info

Publication number
CN104755474A
CN104755474A CN201380052463.6A CN201380052463A CN104755474A CN 104755474 A CN104755474 A CN 104755474A CN 201380052463 A CN201380052463 A CN 201380052463A CN 104755474 A CN104755474 A CN 104755474A
Authority
CN
China
Prior art keywords
kinase
probe
optionally substituted
antibody
tec family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380052463.6A
Other languages
English (en)
Chinese (zh)
Inventor
贝蒂·Y·张
斯特拉·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Publication of CN104755474A publication Critical patent/CN104755474A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201380052463.6A 2012-10-11 2013-10-11 Tec家族激酶抑制剂疗法的伴随诊断 Pending CN104755474A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261712675P 2012-10-11 2012-10-11
US61/712,675 2012-10-11
PCT/US2013/064688 WO2014059368A1 (en) 2012-10-11 2013-10-11 Companion diagnostics for tec family kinase inhibitor therapy

Publications (1)

Publication Number Publication Date
CN104755474A true CN104755474A (zh) 2015-07-01

Family

ID=49510539

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380052463.6A Pending CN104755474A (zh) 2012-10-11 2013-10-11 Tec家族激酶抑制剂疗法的伴随诊断

Country Status (11)

Country Link
US (1) US20150260723A1 (enExample)
EP (1) EP2906556A1 (enExample)
JP (1) JP2015536446A (enExample)
KR (1) KR20150065871A (enExample)
CN (1) CN104755474A (enExample)
AU (1) AU2013328961A1 (enExample)
BR (1) BR112015008042A2 (enExample)
CA (1) CA2887697A1 (enExample)
HK (1) HK1213892A1 (enExample)
MX (1) MX2015004576A (enExample)
WO (1) WO2014059368A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106405086A (zh) * 2016-09-21 2017-02-15 四川大学华西医院 一种肺癌筛查试剂盒
CN109715166A (zh) * 2016-07-14 2019-05-03 深圳明赛瑞霖药业有限公司 癌症的治疗
CN114200145A (zh) * 2022-02-18 2022-03-18 上海益诺思生物技术股份有限公司 酪氨酸激酶浓度的检测方法及试剂盒

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016010961A1 (en) * 2014-07-15 2016-01-21 Abbvie Inc. Enzyme occupancy assay
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
JP2017537327A (ja) 2014-12-11 2017-12-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｂｔｋ阻害剤のアッセイ
WO2016100593A1 (en) * 2014-12-17 2016-06-23 Pharmacyclics Llc Methods and assays for quantification and normalization of kinase and ligand binding
GB201502393D0 (en) * 2015-02-13 2015-04-01 Univ Leicester Senescence
JP6875623B2 (ja) * 2016-02-15 2021-05-26 ノーベルファーマ株式会社 遺伝性疾患に関わるタンパク質の測定方法及び測定キット
US20190376971A1 (en) * 2017-01-19 2019-12-12 Acerta Pharma B.V. Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine Kinase
EP3514541A1 (de) * 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
MX2023014435A (es) 2021-06-04 2024-03-08 Janssen Pharmaceutica Nv Inhibidores de la tirosina quinasa de bruton y métodos de su uso.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989465B2 (en) * 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
AU2009262068C1 (en) * 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715166A (zh) * 2016-07-14 2019-05-03 深圳明赛瑞霖药业有限公司 癌症的治疗
CN115381832A (zh) * 2016-07-14 2022-11-25 深圳明赛瑞霖药业有限公司 癌症的治疗
CN106405086A (zh) * 2016-09-21 2017-02-15 四川大学华西医院 一种肺癌筛查试剂盒
CN114200145A (zh) * 2022-02-18 2022-03-18 上海益诺思生物技术股份有限公司 酪氨酸激酶浓度的检测方法及试剂盒

Also Published As

Publication number Publication date
MX2015004576A (es) 2015-07-21
BR112015008042A2 (pt) 2017-07-04
EP2906556A1 (en) 2015-08-19
HK1213892A1 (zh) 2016-07-15
WO2014059368A1 (en) 2014-04-17
CA2887697A1 (en) 2014-04-17
AU2013328961A1 (en) 2015-05-07
KR20150065871A (ko) 2015-06-15
US20150260723A1 (en) 2015-09-17
JP2015536446A (ja) 2015-12-21

Similar Documents

Publication Publication Date Title
US20150260723A1 (en) Companion diagnostics for tec family kinase inhibitor therapy
AU2006259153B2 (en) Process for the identification of novel enzyme interacting compounds
US20240307537A1 (en) Methods and Compositions for Treating Cancer
ES2403546T3 (es) Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
US20100323389A1 (en) Fluorescent imaging with substituted cyanine dyes
WO2017080338A1 (zh) 丙烯酸类衍生物、其制备方法及其在医药上的用途
JP2018533939A (ja) Ｒａｓの阻害剤をスクリーニングするための方法
KR20120063515A (ko) Ｐｉ３ 키나제 억제제 및 이들의 용도
CA2529238A1 (en) Triazolotriazine compounds and uses thereof
WO2018001232A1 (zh) 丙烯酸类衍生物及其制备方法和其在医药上的用途
WO2016010961A1 (en) Enzyme occupancy assay
US20230321083A1 (en) Inhibitors of GPR174 and Uses Thereof
US11105813B2 (en) Method for target protein identification using thermal stability shift-based fluorescence difference in two-dimensional gel electrophoresis
ES2412380T3 (es) Procedimiento para la identificación de compuestos novedosos que interaccionan con enzimas
US20180051314A1 (en) Compounds, substrates and methods related to histone deacetylases
CN110317855A (zh) 基于细胞的鉴定ido1酶活性及筛选ido1酶抑制剂的荧光检测方法
US20230405135A1 (en) Therapeutic conjugates
WO2016100593A1 (en) Methods and assays for quantification and normalization of kinase and ligand binding
US20240351996A1 (en) Cdk19-selective inhibitors, and methods of use thereof
JP2022527641A (ja) Ｃｘｃｒ４モジュレーターとしてのイミダゾリン誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
CB02 Change of applicant information

Address after: Illinois State

Applicant after: PHARMACYCLICS, Inc.

Address before: California, USA

Applicant before: PHARMACYCLICS, Inc.

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20160901

Address after: California, USA

Applicant after: PHARMACYCLICS LLC

Address before: Illinois State

Applicant before: PHARMACYCLICS, Inc.

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150701

WD01 Invention patent application deemed withdrawn after publication